Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients

Bach Yen Nguyen, Mario Clerici, David J. Venzon, Sergio Bauza, William J. Murphy, Dan L. Longo, Michael Baseler, Neil Gesundheit, Samuel Broder, Gene Shearer, Robert Yarchoan

Research output: Contribution to journalArticle

Abstract

Objective: To study the immunologic effects of recombinant human growth hormone (rhGH), recombinant human insulin-like growth factor type 1 (rhIGF-1), or the combination, in patients with moderately advanced HIV infection. Design: Randomized but not blinded trial. Setting: Government medical research center. Patients: Twenty-four HIV-infected patients with CD4 cell counts of 100-400 x 106/l who were receiving nucleoside antiretroviral therapy. Interventions: Either rhGH, rhIGF-1, or the combination was administered subcutaneously for 12 weeks. Main outcome measures: Immunologic parameters, including T-cell subsets and assays of in vitro interleukin (IL)-2 production in response to antigens and mitogens, and safety profile. Results: Plasma IGF-1 levels were low or low-normal prior to treatment and increased with all three therapies. There were no significant changes in CD4 cell counts, RA/RO CD4 cell subsets, natural killer cell function, immunoglobulin levels, or in vitro IL-2 production in response to mitogen or alloantigens. However, there was an upward trend (and for p18(IIIB) a statistically significant increase) in the in vitro IL-2 production in response to each of five HIV envelope peptides. Potential toxic effects included fatigue, arthralgia, edema, myalgia, and headache. Patients also were noted to have weight gain averaging 4 kg early in the course of treatment. Conclusions: These results suggest that treatment with rhGH/rhIGF-1 was reasonably well tolerated and that modest improvement in HIV-specific immune function was attained. Further studies will help clarify the therapeutic potential of rhGH/rhIGF-1 as an immunostimulator in the setting of HIV infection.

Original languageEnglish
Pages (from-to)895-904
Number of pages10
JournalAIDS (London, England)
Volume12
Issue number8
DOIs
Publication statusPublished - May 28 1998

    Fingerprint

Keywords

  • Cellular immunity
  • Growth hormone
  • Immune reconstitution
  • Immunotherapy
  • Insulin-like growth factor
  • T-cell subset
  • Therapy
  • Wasting

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Nguyen, B. Y., Clerici, M., Venzon, D. J., Bauza, S., Murphy, W. J., Longo, D. L., Baseler, M., Gesundheit, N., Broder, S., Shearer, G., & Yarchoan, R. (1998). Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS (London, England), 12(8), 895-904. https://doi.org/10.1097/00002030-199808000-00012